Teva (TEVA) executive’s RSUs vest and 9,533 shares sold for tax withholding

Rhea-AI Filing Summary

Teva Pharmaceutical Industries executive Eric A. Hughes reported equity awards activity and a related share sale. On March 5, 2026, 19,654 restricted share units vested and were converted into 19,654 ordinary shares at no cost, increasing his direct holdings to 117,244 ordinary shares.

On the same date, he sold 9,533 ordinary shares at a weighted average price of $31.6684 per share, reducing his direct holdings to 107,711 ordinary shares. According to the disclosure, these shares were sold under a pre-established Rule 10b5-1 trading plan and were required to cover tax withholding obligations from the RSU vesting.

Footnotes add that each restricted share unit represents a right to receive one ordinary share or its cash value, and that the RSU grant from March 5, 2025 vests in four equal annual installments through March 5, 2029.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hughes Eric A

(Last) (First) (Middle)

C/O TEVA PHARMACEUTICAL INDUSTRIES LTD.

124 DVORA HANEVI'A ST.,

(Street)

TEL AVIV L3 6944020

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
TEVA PHARMACEUTICAL INDUSTRIES LTD [ TEVA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See "Remarks"

3. Date of Earliest Transaction (Month/Day/Year)
03/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares(1)	03/05/2026		M		19,654	A	(2)	117,244	D
Ordinary Shares(1)	03/05/2026		S(3)		9,533(4)	D	$31.6684(5)	107,711	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Share Units	(2)	03/05/2026		M			19,654	(6)	(6)	Ordinary Shares(1)	19,654	$0	58,962	D

Explanation of Responses:

1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

2. Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

3. The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2025.

4. Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.

5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.26 to $32.34, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

6. Restricted share units were granted on March 5, 2025, with 19,654 vested on March 5, 2026, and 19,654 vesting on each of March 5, 2027, March 5, 2028 and March 5, 2029.

Remarks:

Executive Vice President, Global R&D and Chief Medical Officer

	/s/ Dov Bergwerk as attorney-in-fact for Eric A. Hughes	03/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Eric A. Hughes report for TEVA?

Eric A. Hughes reported RSU vesting and a related share sale. 19,654 restricted share units vested into 19,654 ordinary shares, and 9,533 ordinary shares were sold to cover tax withholding obligations tied to that vesting under a Rule 10b5-1 trading plan.

How many Teva (TEVA) shares did Eric A. Hughes sell and at what price?

He sold 9,533 ordinary shares of Teva at a weighted average price of $31.6684 per share. The filing notes these shares were sold in multiple transactions between $31.26 and $32.34, all executed under a pre-established Rule 10b5-1 trading plan.

Why did Eric A. Hughes sell Teva (TEVA) shares in this Form 4?

The sale of 9,533 Teva ordinary shares was made to cover tax withholding obligations arising from the vesting of restricted share units. The disclosure states the transaction was executed under a Rule 10b5-1 trading plan previously adopted by the reporting person.

How did the RSU vesting affect Eric A. Hughes’ Teva share holdings?

19,654 restricted share units vested and converted into 19,654 ordinary shares, increasing his direct ordinary share holdings to 117,244 before the tax-related sale. After selling 9,533 shares, his direct holdings stood at 107,711 Teva ordinary shares according to the reported figures.

What is the vesting schedule of Eric A. Hughes’ Teva restricted share units?

Restricted share units were granted on March 5, 2025, with 19,654 units vesting on March 5, 2026. Additional tranches of 19,654 units are scheduled to vest on March 5 of 2027, 2028, and 2029, subject to the terms of the award.

How are Teva (TEVA) restricted share units settled for Eric A. Hughes?

Each restricted share unit represents a contingent right to receive, at settlement, one Teva ordinary share or, at the Human Resources and Compensation Committee’s option, the cash value of one ordinary share, as described in the filing’s footnotes.